Drugs / 10-1074
10-1074
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT04340596 | May 2021 → Jun 2026 overdue | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04811040 | Apr 2021 → Jun 2022 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT03588715 | Jun 2020 → Dec 2021 | AIDS | Luis Montaner | Unknown | No outcome recorded |
| Phase 1 | NCT03928821 | Jul 2019 → Mar 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03571204 | Sep 2018 → Mar 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1 | NCT03526848 | Jun 2018 → Sep 2021 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT02824536 | Jun 2016 → Jan 2018 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT02825797 | Jun 2016 → Aug 2018 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT02511990 | Jul 2015 → Dec 2016 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04357821 | Aug 2020 → Jun 2026 overdue | HIV infectious disease | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03707977 | Jun 2019 → Dec 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05729568 | May 2023 → Jul 2024 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04720742 | Feb 2021 → Mar 2022 | HIV infectious disease | IrsiCaixa | Withdrawn | No outcome recorded Stop: Business |
| Phase 32 trials | ||||||
| Phase 3 | NCT07683000 | Jul 2026 → Mar 2029 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07682961 | Jul 2026 → Mar 2029 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03831945 Comparator | Apr 2019 → Dec 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03837756 Comparator | May 2019 → Jul 2022 | HIV infectious disease | University of Aarhus | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-03-12 | Gilead Sciences | Results Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option gilead.com ↗
At CROI 2025, the primary results of a Phase 2 study evaluating the investigational combination of LTZ were presented during an oral session and featured in the press program; those data announced at CROI confirm previously presented Phase 1b results. |
| 2024-11-12 | Gilead Sciences | Results Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline gilead.com ↗
At Week 26, 21% (n=3) of participants who received LEN + TAB and the low dose of ZAB and 0% (n=0) participants who received LEN +TAB and the high dose of ZAB had an HIV viral load ≥50 copies/mL (per FDA Snapshot). |
| 2024-03-05 | Gilead Sciences | Results Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health gilead.com ↗
In a recent Phase 1b study published in The Lancet HIV , the investigational combination of lenacapavir + teropavimab (GS-5423, TAB) + zinlirvimab (GS-2872, ZAB) demonstrated high efficacy and maintained virologic suppression for six months with twice-yearly dosing. |
| 2023-02-22 | Gilead Sciences | Results Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV gilead.com ↗
Results fromthe Phase 1b clinical trial demonstrated the investigational combination was generally well tolerated with high efficacy in select virologically suppressed participants living with HIV. |
| 2023-02-21 | Gilead Sciences | Results Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies gilead.com ↗
Results from the Phase 2a TITAN trial show that dual treatment with the broadly neutralizing HIV antibodies (bNAbs; 3BNC117 and 10-1074) led to a significant delay in viral rebound. |
All press releases naming this drug 5 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 10-1074 | “During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074” NCT04720742 ↗12“single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively)” NCT04357821 ↗ |
| Known as | Monoclonal Antibody 10-1074 | “Monoclonal Antibody 10-1074” NCT02824536 ↗ |
| Known as | Zinlirvimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07682961 ↗ |
| Action | Inhibit | “suppress viral replication in subjects who are not taking ART” NCT03571204 ↗ |
| Modality | Monoclonal antibody | “10-1074 Monoclonal Antibody” NCT02511990 ↗ |
| Route | Intravenous | “single dose IV administration of 10-1074” NCT02511990 ↗ |